Skip to main content
Smart Investors Daily
TE

NYSE · TEVA

Teva Pharmaceutical Industries Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$42.57

Down-$1.93 (-4.34%)

Updated Nov 17, 2026, 3:11 AM

SID Score

7.1/10

Composite research score

Smart Money

56/100

Neutral

Market cap
34.61B
P/E ratio
-217.43
Dividend yield
0.00%
52-week range
$24.01 – $44.57
Volume
7.46M
Avg. volume
11.34M

Price performance · TEVA

TEVA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

TEVA closed at $42.57 after 21 trading sessions, up 3.05% for the selected period.

Last close
$42.57
Period change
+3.05%
Period low
$39.41
Period high
$44.50
Daily close
View OHLC price history
TEVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$44.30$44.57$42.52$42.577.46M
Nov 13, 2026$43.91$44.565$43.43$44.507.56M
Nov 12, 2026$43.52$44.31$43.185$43.659.25M
Nov 11, 2026$42.71$43.24$42.385$43.249.56M
Nov 10, 2026$42.46$42.69$41.64$42.406.22M
Nov 9, 2026$43.01$43.18$42.66$42.974.58M
Nov 6, 2026$41.47$42.63$41.41$42.616.2M
Nov 5, 2026$41.49$42.38$40.9247$41.7813.71M
Nov 4, 2026$41.89$42.59$41.29$41.8510.04M
Nov 3, 2026$41.905$43.34$41.54$41.9111.67M
Nov 2, 2026$41.12$42.00$40.63$40.7010.59M
Oct 30, 2026$41.17$42.59$41.17$42.097.36M
Oct 29, 2026$40.14$41.67$40.01$41.475.23M
Oct 28, 2026$39.74$40.50$39.46$39.974.65M
Oct 27, 2026$39.71$40.86$39.71$40.395.98M
Oct 26, 2026$39.22$40.115$39.15$39.956.03M
Oct 23, 2026$39.75$39.8399$39.105$39.415.6M
Oct 22, 2026$40.20$40.445$39.58$40.214.07M
Oct 21, 2026$40.18$41.09$39.50$40.624.6M
Oct 20, 2026$41.48$41.59$40.80$40.854.22M
Oct 19, 2026$41.42$41.8792$41.25$41.313.83M

Latest TEVA news

The latest Smart Investors Daily articles mentioning TEVA.

TEVA research

Overview

Company profile and research snapshot.

Company profile

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$32.67
Implied upside
—
Analysts
—
TEVA recent ratings
DateFirmRatingTarget
Nov 25, 2020OppenheimerPerform—
Nov 6, 2020BMO CapitalMarket Perform—
Aug 6, 2020BarclaysEqual-Weight—
Aug 6, 2020SVB LeerinkMarket Perform—
Jul 27, 2020Goldman SachsNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 14, 2026

AJOVY® Formally Included in China's National Reimbursement Drug List 2026

On November 14, NeuroGen announced that it's in-licensed innovative drug AJOVY® (fremanezumab injection) from TEVA has been successfully listed on China's National Reimbursement Drug List (NRDL) following the latest round of national price negotiations1. Marking a breakthrough as the first CGRP inhibitor covered by national insurance, AJOVY® achieved same-year NRDL inclusion after its initial approval in June—a milestone expected to dramatically improve patient access and relieve the long-term f

Yahoo · Nov 12, 2026

Teva Pharmaceutical Industries (TEVA) Holds First R&D Day With New Pipeline Milestones

Teva Pharmaceutical Industries (NYSE:TEVA) hosted its first R&D Day at the New York Stock Exchange in November 2026. Management outlined a long term growth plan centered on higher value medicines and a shift in the company’s product mix. The firm highlighted progress in its pipeline, including new first in class therapies and updates on late stage clinical programs. Teva’s inaugural R&D Day pipeline push, including first in class therapies, needs to be seen alongside a broader set of facts...

Yahoo · Nov 12, 2026

Teva Pharmaceutical Industries (TEVA) Earnings Put Its Turnaround Valuation Back In Focus

Teva Pharmaceutical Industries (NYSE:TEVA) just delivered third quarter 2026 earnings, reporting sales of US$4.4b and net income of US$233m, along with higher impairment charges and a slightly raised full year revenue outlook. The latest earnings release lands after a strong share price run for Teva Pharmaceutical Industries, with the stock delivering a 31.67% year to date share price return and a 16.86% share price gain over the past 90 days. The 3 year total shareholder return of about 4x...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.